Last updated: March 2, 2026
What is NDC 46122-0457?
NDC 46122-0457 corresponds to Ozempic (semaglutide), an injectable medication indicated for type 2 diabetes management and weight reduction. Manufactured by Novo Nordisk, it gained FDA approval in 2017 and became a significant player within the GLP-1 receptor agonist market.
Market Landscape
Current Market Size
- Global diabetes drug market in 2022 was valued at approximately $35 billion.
- GLP-1 receptor agonists comprise an estimated $7 billion of this segment.
- Ozempic accounts for roughly 30% of the GLP-1 market, estimated at $2.1 billion in 2022.
Competitive Position
- Ozempic faces competition from drugs like Eli Lilly's Trulicity (dulaglutide), AstraZeneca's Bydureon (exenatide), and newer agents like Tirzepatide (Mismo), which is marketed as a dual GIP/GLP-1 receptor agonist.
- Trulicity holds about 23% of the GLP-1 market, followed by Ozempic at approximately 30%.
Market Trends
- Rising prevalence of type 2 diabetes and obesity increases demand.
- Transition towards once-weekly injections improves patient compliance.
- Expanding approvals: In 2022, Ozempic's label expanded to include weight management indications for obesity.
Regulatory Approvals and Guidance
- FDA approved Ozempic for diabetes treatment in 2017.
- In June 2021, FDA approved a higher-dose formulation for weight management: Wegovy (semaglutide 2.4 mg).
- Planned launches of oral semaglutide formulations, blending convenience with therapeutic efficacy.
Price Analysis
Current Pricing
- List price for Ozempic in the U.S. averages $900 - $1,000 per four-week supply.
- Manufacturer discounts and pharmacy benefit manager (PBM) negotiations lower net prices.
- Patient co-pay assistance programs reduce out-of-pocket costs for eligible patients.
Price Trends
- Steady increase in price since FDA approval due to manufacturing costs and demand.
- New formulations (e.g., oral semaglutide) priced around $850 - $900 per month.
- Price escalations approximately 5-8% annually over the past three years.
Reimbursement Dynamics
- Reimbursement rates depend heavily on insurance and PBMs.
- Introduction of biosimilars is limited, providing limited price competition.
- Negotiated discounts and formularies influence actual net prices for payers.
Future Price Projections (Next 5 Years)
| Year |
Projected List Price (USD) |
Assumptions |
| 2024 |
$1,050 - $1,100 |
Continued demand and patient access expansion |
| 2025 |
$1,100 - $1,150 |
Patent protections maintain market exclusivity |
| 2026 |
$1,150 - $1,200 |
Launch of oral formulations and expanded indications |
| 2027 |
$1,200 - $1,250 |
Slight market saturation; incremental pricing |
| 2028 |
$1,250 - $1,300 |
Potential for biosimilar competition; price stabilization |
Pricing Influences
- Birth of biosimilars or generics could reduce prices by 20-30%, but current patent protections limit this until at least 2028.
- Policy measures aiming to curtail drug prices could exert downward pressure.
- The introduction of oral semaglutide may affect patient preferences and impact injectable sales, potentially influencing pricing strategies.
Market Opportunities and Risks
Opportunities
- Growth in obesity treatment expands the therapeutic area.
- Potential new indications, including cardiovascular and non-alcoholic steatohepatitis (NASH).
- Strategic partnerships with payers to optimize formulary placement.
Risks
- Patent expirations could introduce biosimilars, impacting revenue.
- Competition from alternative therapies, especially oral formulations, could erode market share.
- Policy reforms and price controls may limit profit margins.
Key Takeaways
- NDC 46122-0457 (Ozempic) holds a dominant position in the GLP-1 class, with steady revenue growth driven by increasing demand for diabetes and obesity treatments.
- Current prices hover around $900-$1,000 per four-week supply, with upward trends continuing due to demand and premium formulations.
- Price projections suggest a potential increase to $1,200-$1,300 by 2028, barring biosimilar entry or policy interventions.
- The market faces intensifying competition from oral semaglutide and dual GIP/GLP-1 therapies.
- Strategic positioning around expanding indications and improved patient access remains critical for maintaining market share.
FAQs
Q1: When can biosimilars for semaglutide be expected?
A1: Biosimilar development is ongoing, but patent protections extend until at least 2028, delaying biosimilar entry.
Q2: How does the introduction of oral semaglutide affect the market?
A2: It offers a more convenient option, potentially expanding the patient base. It could cannibalize some injectable sales but also increase overall market size.
Q3: What are the primary drivers for price increases?
A3: Demand growth, premium formulations, inflation in manufacturing costs, and limited biosimilar competition.
Q4: How do reimbursement policies influence Ozempic's net price?
A4: Negotiated discounts, formulary placements, and patient co-payment assistance directly impact the net price received by Novo Nordisk.
Q5: What emerging indications could influence Ozempic's future market?
A5: Cardiovascular risk reduction, weight management beyond obesity, and NASH are potential growth areas.
References
[1] IQVIA. (2023). Global Prescription Drug Market Report.
[2] FDA. (2021). Wegovy (semaglutide) Approval Announcement.
[3] Novo Nordisk. (2023). Ozempic Product Information.
[4] Evaluate Pharma. (2022). 2022 Market Data and Projections.
[5] Centers for Disease Control and Prevention. (2022). Diabetes Statistics.
